Jefferies Group’s Esperion Therapeutics ESPR Stock Holding History

Jefferies Group’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,008	Closed	-$253K	–	1755
2021 Q1	$253K	Buy	+9,008	New	+$266K	﹤0.01%	1292
2020 Q1	–	Sell	-10,000	Closed	-$596K	–	2209
2019 Q4	$596K	Sell	10,000 -9,463	-49%	-$425K	﹤0.01%	1709
2019 Q3	$714K	Buy	19,463 +11,112	+133%	+$440K	0.01%	1686
2019 Q2	$388K	Buy	+8,351	New	+$392K	﹤0.01%	1794
2015 Q1	–	Sell	-7,300	Closed	-$471K	–	2176
2014 Q4	$295K	Buy	+7,300	New	+$223K	﹤0.01%	1555

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jefferies Group's ESPR Position: Q2 2021 in Review

Jefferies Group sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 9,008 shares — an estimated $253K sold.

Jefferies Group first reported a position in ESPR in Q4 2014 and held it in 5 quarters. The position peaked at $714K in Q3 2019. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

Jefferies Group reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 9,008 Esperion Therapeutics shares in Q2 2021, an estimated $253K.
Jefferies Group first reported a position in Esperion Therapeutics in Q4 2014 and held it in 5 quarters.
Jefferies Group's Esperion Therapeutics position peaked at $714K in Q3 2019.
142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.